Bicara Therapeutics (NASDAQ:BCAX) Posts Quarterly Earnings Results, Misses Expectations By $0.22 EPS

Bicara Therapeutics (NASDAQ:BCAX) announced its quarterly earnings results on Monday. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22), FiscalAI reports.

Bicara Therapeutics Price Performance

BCAX opened at $8.65 on Monday. Bicara Therapeutics has a 12 month low of $7.87 and a 12 month high of $30.99. The stock has a market capitalization of $572.40 million, a price-to-earnings ratio of -2.79 and a beta of -0.33. The business has a fifty day moving average price of $18.16 and a 200 day moving average price of $20.95.

Insider Buying and Selling at Bicara Therapeutics

In related news, CEO Ryan Cohlhepp sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total value of $400,750.00. Following the sale, the chief executive officer owned 181,641 shares of the company’s stock, valued at $4,159,578.90. This trade represents a 8.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Benchmark reiterated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, October 29th. Wall Street Zen cut Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 31st. Wells Fargo & Company lifted their target price on Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 12th. The Goldman Sachs Group lowered Bicara Therapeutics from a “neutral” rating to a “sell” rating and decreased their price target for the company from $20.00 to $8.00 in a research note on Friday, October 30th. Finally, Wedbush lowered their price target on Bicara Therapeutics from $33.00 to $24.00 and set an “outperform” rating for the company in a report on Thursday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $30.91.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression.